We have found that CRBN expression is required for the anti-myeloma activity of IMiDs [18] and introduction of wild-type or His-tagged CRBN into IMiD-resistant cells increased their sensitivities to IMiD [17]. The gene discussed is CRBN; the disease is plasma cell myeloma.